To minimise the impact on healthy tissues, we have developed a dual targeting strategy to specifically deliver to the skin tumour tissues based on the fact that skin cancer cells overexpress programmed death ligand-1 (PD-L1) [15] and folate receptors [16] as surface proteins. The gene discussed is CD274; the disease is skin neoplasm.